文献速递乳腺癌

Chemo-prAIdict Breast:预测乳腺癌新辅助化疗后残留病灶的深度学习模型

Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.
PubMed 文献 · Eur J Cancer · 2026-01-07

该研究开发了基于诊断活检全切片图像的深度学习模型Chemo-prAIdict Breast,用于预测早期乳腺癌患者新辅助化疗后的残留病灶。模型在法国多中心前瞻性PRIMUNEO队列(n=500,筛选后438)中训练和内部验证,在CGFL回顾性队列(n=640,筛选后490)中独立外部验证。外部验证中,模型在HER2+、ER+/HER2-和三阴性肿瘤中的AUC分别为0.652(p=0.001)、0.814(p=0.003)和0.677(p=0.001),优于标准临床病理特征。

要点

  • 模型在ER+/HER2-亚型预测性能最佳,外部验证AUC为0.814。
  • 连续切片预测高度一致(Pearson r≥0.932),显示稳健性。
  • 需前瞻性研究验证临床实用性,目前尚不能直接指导治疗决策。

核心结论

  • Chemo-prAIdict Breast可识别对标准新辅助化疗敏感性不同的早期乳腺癌,有望辅助治疗策略选择。

研究设计与样本

  • 开发基于诊断活检全切片图像的深度学习模型,使用两个法国队列:前瞻性多中心PRIMUNEO队列(n=500,筛选后438)用于训练和内部验证,回顾性CGFL队列(n=640,筛选后490)用于独立外部验证。

主要发现

  • 外部验证中,模型预测残留病灶的AUC在HER2+肿瘤为0.652(p=0.001),ER+/HER2-为0.814(p=0.003),三阴性为0.677(p=0.001),均优于标准临床病理特征。
  • 使用421例患者的配对连续活检切片验证稳健性,患者内预测强相关(Pearson r:HER2+ 0.933,ER+/HER2- 0.932,三阴性 0.939;均p<0.001)。

临床怎么用

  • 该工具尚处于研究阶段,需前瞻性研究采用现代治疗方案确认临床效用后,方可用于指导HER2+、ER+/HER2-和三阴性早期乳腺癌的新辅助化疗决策。

局限性

  • 需要前瞻性研究采用现代治疗方案来确立临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predicting chemosensitivity before treatment could help tailor neoadjuvant chemotherapy (NAC) in early breast cancer (eBC). Pathological complete response (pCR) is associated with better long term survival, but yet no robust baseline predictor is available. PATIENTS AND METHODS: We developed Chemo-prAIdict Breast, a deep learning model using whole slide images (WSIs) of diagnostic biopsies to predict residual disease (RD) after NAC. Two large French cohorts were analyzed (n = 1140 initially included, 928 analyzed after selection): the prospective multicenter PRIMUNEO cohort (n = 500, 438 after selection) for training and internal validation, and the CGFL retrospective cohort (n = 640, 490 after selection) for independent external validation. Patients were stratified by molecular subtype: HER2-amplified (HER2 +), ER-positive/HER2-negative (ER+/HER2 -), and triple-negative (TN). RESULTS: In external validation, Chemo-prAIdict Breast outperformed standard clinicopathological features, achieving AUCs of 0.652 (p = 0.001) in HER2 + , 0.814 (p = 0.003) in ER+ /HER2 -, and 0.677 (p = 0.001) in TN tumors. Robustness was confirmed using paired consecutive biopsy sections from 421 patients: predictions were strongly correlated within patients (Pearson r = 0.933 for HER2 +, 0.932 for ER+/HER2 -, 0.939 for TN; all p < 0.001). CONCLUSIONS: While prospective studies with modern treatment regimens are needed to establish clinical utility, Chemo-prAIdict Breast is a new tool for identifying eBC that are differentially sensitive to standard NAC, and could help to select the most appropriate treatment strategy in HER2 + , ER+ /HER2- and TN eBC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Valderrama NF, Morel LO, Mweze DT, et al. Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. Eur J Cancer. 2026. PMID: 41518683. doi:10.1016/j.ejca.2026.116222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。